Maine Biotechnology Services, Inc. is pleased to announce the addition of Dr. Jennifer Walker as the MBS Hybridoma Project Manager. Dr. Walker brings additional depth to the scientific team that works with customers to develop rich project plans that shorten timelines and mitigate risks. She will be responsible for management and execution of those project plans, as well as analyzing and communicating data to facilitate timely, goal-driven decision making throughout the hybridoma development process.
Prior to joining MBS, Dr. Walker was a doctoral candidate and research associate at the University of Maine focusing on B cell development, protein biochemistry, and cell signaling aberrations that permit the survival and development of autoimmune B cells.
Dr. Walker’s education includes a B.A. in Biology from Franklin Pierce University, dual Master’s degrees in Secondary Science Education and Molecular Biology from Sienna Heights University and the University of Southern Maine respectively, and a Ph.D. in Biochemistry and Molecular Biology from the University of Maine.
“I am very excited to have Dr. Walker join MBS as the Hybridoma Development Project Manager. She completed her M.S. and Ph.D. in my laboratory working on autoimmunity, B cell development, and plasma cell differentiation; and with that experience she brings her vast technical understanding and knowledge of immunology, molecular biology, antibodies and B cell biology to the MBS Hybridoma Project Development team.” noted Dr. Stephen Pelsue, MBS Science Director.
Dr. Walker joined Maine Biotechnology Services in June of 2016 and is already bringing her knowledge, experience, and technical skills to the development of monoclonal antibodies for our customer base.